Virginiamycin S1
Star0
Identification
- Generic Name
- Virginiamycin S1
- DrugBank Accession Number
- DB04805
- Background
One of the components of virginiamycin, a cyclic polypeptide antibiotic complex from streptomyces virginiae, s. Loidensis, s. Mitakaensis, s. Pristina-spiralis, s. Ostreogriseus, and others. It is used to treat infections with gram-positive organisms and as a growth promoter in cattle, swine, and poultry.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
- Weight
- Average: 823.904
Monoisotopic: 823.354090806 - Chemical Formula
- C43H49N7O10
- Synonyms
- Staphylomycin S
- Staphylomycin S1
- Virginiamycin factor S
- Virginiamycin factor S1
- External IDs
- Antibiotic 1754Z3B
- NSC-177858
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism U60S ribosomal protein L37 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as cyclic depsipeptides. These are natural or synthetic compounds having sequences of amino and hydroxy carboxylic acid residues (usually α-amino and α-hydroxy acids) connected in a ring. The residues are commonly but not necessarily regularly alternating.
- Kingdom
- Organic compounds
- Super Class
- Organic acids and derivatives
- Class
- Peptidomimetics
- Sub Class
- Depsipeptides
- Direct Parent
- Cyclic depsipeptides
- Alternative Parents
- Macrolide lactams / Alpha amino acid esters / Macrolactams / N-acyl-alpha amino acids and derivatives / Pyridinecarboxamides / 2-heteroaryl carboxamides / Hydroxypyridines / Piperidinones / Benzene and substituted derivatives / Vinylogous acids show 15 more
- Substituents
- 2-heteroaryl carboxamide / Alpha-amino acid ester / Alpha-amino acid or derivatives / Aromatic heteropolycyclic compound / Azacycle / Benzenoid / Carbonyl group / Carboxamide group / Carboxylic acid derivative / Carboxylic acid ester show 30 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- macrolide antibiotic, cyclodepsipeptide (CHEBI:46416)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- J91D5GN5AT
- CAS number
- 23152-29-6
- InChI Key
- FEPMHVLSLDOMQC-IYPFLVAKSA-N
- InChI
- InChI=1S/C43H49N7O10/c1-4-29-40(56)49-21-12-17-30(49)41(57)48(3)32(23-26-13-7-5-8-14-26)42(58)50-22-19-28(51)24-31(50)37(53)47-35(27-15-9-6-10-16-27)43(59)60-25(2)34(38(54)45-29)46-39(55)36-33(52)18-11-20-44-36/h5-11,13-16,18,20,25,29-32,34-35,52H,4,12,17,19,21-24H2,1-3H3,(H,45,54)(H,46,55)(H,47,53)/t25-,29-,30+,31+,32+,34+,35+/m1/s1
- IUPAC Name
- N-[(3S,6S,12R,15S,16R,19S,22S)-3-benzyl-12-ethyl-4,16-dimethyl-2,5,11,14,18,21,24-heptaoxo-19-phenyl-17-oxa-1,4,10,13,20-pentaazatricyclo[20.4.0.0⁶,¹⁰]hexacosan-15-yl]-3-hydroxypyridine-2-carboxamide
- SMILES
- [H][C@@]12CCCN1C(=O)[C@@H](CC)NC(=O)[C@@H](NC(=O)C1=NC=CC=C1O)[C@@H](C)OC(=O)[C@@H](NC(=O)[C@]1([H])CC(=O)CCN1C(=O)[C@]([H])(CC1=CC=CC=C1)N(C)C2=O)C1=CC=CC=C1
References
- General References
- Not Available
- External Links
- KEGG Compound
- C11269
- PubChem Compound
- 5388936
- PubChem Substance
- 46507514
- ChemSpider
- 4534976
- ChEBI
- 46416
- ChEMBL
- CHEMBL1236684
- ZINC
- ZINC000094313271
- Wikipedia
- Virginiamycin_S1
Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.139 mg/mL ALOGPS logP 2.25 ALOGPS logP 1.85 Chemaxon logS -3.8 ALOGPS pKa (Strongest Acidic) 7.53 Chemaxon pKa (Strongest Basic) 1.57 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 10 Chemaxon Hydrogen Donor Count 4 Chemaxon Polar Surface Area 224.72 Å2 Chemaxon Rotatable Bond Count 6 Chemaxon Refractivity 213.24 m3·mol-1 Chemaxon Polarizability 82.42 Å3 Chemaxon Number of Rings 6 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule Yes Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption - 0.6797 Blood Brain Barrier - 0.9962 Caco-2 permeable - 0.733 P-glycoprotein substrate Substrate 0.8305 P-glycoprotein inhibitor I Non-inhibitor 0.7713 P-glycoprotein inhibitor II Non-inhibitor 0.6866 Renal organic cation transporter Non-inhibitor 0.8908 CYP450 2C9 substrate Non-substrate 0.8155 CYP450 2D6 substrate Non-substrate 0.897 CYP450 3A4 substrate Substrate 0.6366 CYP450 1A2 substrate Non-inhibitor 0.9179 CYP450 2C9 inhibitor Non-inhibitor 0.8335 CYP450 2D6 inhibitor Non-inhibitor 0.823 CYP450 2C19 inhibitor Non-inhibitor 0.8524 CYP450 3A4 inhibitor Non-inhibitor 0.882 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9079 Ames test Non AMES toxic 0.8103 Carcinogenicity Non-carcinogens 0.8855 Biodegradation Not ready biodegradable 0.966 Rat acute toxicity 3.0523 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9287 hERG inhibition (predictor II) Inhibitor 0.6534
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 282.1344892 predictedDarkChem Lite v0.1.0 [M-H]- 265.55893 predictedDeepCCS 1.0 (2019) [M+H]+ 267.28262 predictedDeepCCS 1.0 (2019) [M+Na]+ 273.9482 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. Details60S ribosomal protein L37
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Structural constituent of ribosome
- Specific Function
- Binds to the 23S rRNA.
- Gene Name
- RPL37
- Uniprot ID
- P61927
- Uniprot Name
- 60S ribosomal protein L37
- Molecular Weight
- 11077.81 Da
References
- Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
Drug created at September 11, 2007 17:49 / Updated at June 12, 2020 16:52